Dermata Therapeutics Inc. (DRMA)
1.37
-0.07 (-4.86%)
At close: Jan 15, 2025, 11:53 AM
undefined% (undefined)
| Bid | 1.34 |
| Market Cap | 2.81M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -13.36 |
| PE Ratio (ttm) | -0.1 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.38 |
| Volume | 49,650 |
| Avg. Volume (20D) | 332,606 |
| Open | 1.41 |
| Previous Close | 1.44 |
| Day's Range | 1.32 - 1.42 |
| 52-Week Range | 1.00 - 8.65 |
| Beta | undefined |
About DRMA
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phas...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMA
Website https://www.dermatarx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DRMA stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 336.40% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+19.01%
Dermata Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago ·
Source
+7.41%
Dermata Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
